GSK Halts Development Of Vertex’ Brecanavir Due To Formulation Concerns

The investigational protease inhibitor was in Phase II development for the treatment of HIV.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet